Revolution Medicines (RVMD) CCO Anthony Mancini Sells Shares

What Happened
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines (RVMD), sold a total of 3,708 shares in two transactions and exercised stock options that same period. On 2026-09-24 he sold 587 shares at $200.00 each for $117,400. On 2026-09-25 he exercised 3,121 options at $33.62 (cost $104,928), and those 3,121 shares were sold the same day at $200.54 for $625,885. The Form 4 also records a derivative disposition entry related to the exercise.

Key Details

• Transaction dates: 2026-09-24 (sale of 587 shares @ $200.00) and 2026-09-25 (option exercise and sale of 3,121 shares @ $200.54).
• Sale proceeds: $117,400 (9/24) + $625,885 (9/25) = $743,285 total. Exercise cost: $104,928.
• Derivative entry: a 3,121-share derivative disposition at $0 is reported (reflects the option conversion/settlement).
• Footnotes: Transaction on 9/24 was made pursuant to a 10b5-1 trading plan adopted by Mancini on June 11, 2026 (F1). Filing notes 39,575 restricted stock units are included in holdings (F2). Vesting schedule for the option is detailed (1/4 after 1 year from 4/1/2025, then monthly vesting over 4 years) (F3).
• Timeliness: Form 4 covers transactions dated 9/24–9/25 and was filed on 2026-09-28, which is within the SEC’s two-business-day reporting window.

Context

• The 9/25 activity shows an option exercise followed by an immediate sale of the exercised shares (a cashless or same-day disposition), which is a common way to realize intrinsic value and cover exercise/tax costs.
• The 9/24 sale was executed under a pre-established 10b5-1 plan, indicating trades were pre-planned rather than ad hoc.
• These are routine insider transactions; factual reporting shows the amounts but does not indicate the insider’s motives.